Life Sciences

Research

Help de-risk and accelerate the path to clinic

Learn more

Disease Biology

Uncover deeper insights regarding tumor heterogeneity, resistance mechanisms, and interaction within the tumor microenvironment to support targeted development strategies. Integrate tumor organoid models, multimodal data, multi-omic profiling, and AI-driven analytics to map oncogenic pathways, characterize immune evasion strategies, and identify tumor vulnerabilities.

Learn more

Drug screening with advanced imaging capabilities

Learn how noninvasive imaging techniques allow for continuous study of organoids.

Characterizing Unmet Needs

Leverage real-world data and epidemiological modeling to quantify disease burden and survival disparities, helping uncover potential resistance-associated biomarkers and high-impact subpopulations. Evaluate treatment gaps through real-world evidence to guide development prioritization.

Learn more

Bristol Myers Squibb Collaboration

Identifying and validating targets with multimodal data, computation, and patient-derived models.

Clinical Trial Design

Real-world Outcomes & Value

Target Validation & Lead Optimization

Explore a target’s involvement in cancer progression and therapeutic actionability. Assess target expression, function, and druggability using tumor organoid models to evaluate its biological relevance. Leverage real-world toxicity, resistance, and treatment-response data to further validate targets and refine drug candidates.

Learn more

Validating Immune Profile Score (IPS)

Dr. Michelle Ting-Lin, discusses the science behind a novel biomarker and ICI prognosticator.

Biomarker Strategy

Validate and refine biomarkers using tumor organoids and multimodal data to assess predictive, prognostic, or pharmacodynamic utility. Leverage insights generated to optimize patient stratification and response monitoring throughout clinical development.

Learn more

Advancing immunotherapy biomarker identification

Jason Blue-Smith discusses IO biomarker challenges and how Tempus IPS provides solutions.

Clinical Trial Execution

Care Gaps Closure

Novel Target Identification

Investigate possible novel target candidates while considering oncogenic dependencies via high-throughput functional screening. Refine candidate selection using computational modeling and AI-powered omics solutions to predict druggability, pathway redundancy, and tumor specificity. Investigate therapeutic relevance of emerging targets through validation studies using tumor organoid models, enabling a data-based prioritization of first-in-class or best-in-class therapeutic approaches.

Learn more

Harnessing AI with multimodal data

Dr. Kate Sasser, PhD, discusses layering ML and AI on RWD to drive insights in drug discovery.

Indication Selection

Identify tumor types and patient populations that may benefit from a therapeutic candidate by integrating disease biology, biomarker insights, and clinical unmet needs. Refine clinical development strategies to support efficient resource allocation and increase the probability of technical success.

Learn more

Clin Dev Clinical Trial Design and Indication Selection

Revolutionize drug screening

How Tempus AI’s imaging enables continuous organoid study across assays, preserving testing viability.

IUO Validation & CDx Development

Clinical Development

Boost confidence at each developmental milestone

Learn more

Disease Biology

Characterizing Unmet Needs

Clinical Trial Design

Analyze contemporaneous, real-world, multimodal data to characterize tumor heterogeneity, enabling the integration of those insights into trial I/E criteria. Refine trial endpoints to improve the probability of technical success and effectively evaluate drug efficacy across diverse patient populations. Assess the impact of different methods for generating standard-of-care performance data as comparators.

Learn more

Strategically simulate and contextualize data

Mirati leverages Tempus RWD to revise its KRAS strategy and refine patient selection.

Real-world Outcomes & Value

Target Validation & Lead Optimization

Biomarker Strategy

Leverage multimodal data to refine biomarker-driven patient selection criteria and optimize trial design for regulatory review. Integrate biomarker assays into clinical trial workflows to help maximize the probability of technical success and accelerate the path toward CDx submission.

Learn more

Case Study AstraZeneca reduces time to launch

Reduce time to launch with multimodal data

Learn how AstraZeneca simplified its approach to TROPION-Lung01 and drove down time to launch.

Clinical Trial Execution

Optimize site selection and leverage real-world data for feasibility assessments. Tap into an extensive provider network equipped with algorithmic patient-matching workflows to accelerate enrollment. Execute clinical trials efficiently by leveraging data-driven insights.

Learn more

Activate trial sites faster

Sermonix was able to accelerate timelines for first patient in and enrollment by working with Tempus.

Care Gaps Closure

Novel Target Identification

Indication Selection

Explore multimodal datasets and leverage AI-driven analytics to investigate indications with high unmet need. Implement a strategic approach to indication selection informed by tumor heterogeneity across subpopulations and standard of care landscape dynamics to help optimize resource allocation, accelerate time to market, and expand label opportunities.

Learn more

PAVO: Assessing the safety and efficacy of niraparib (PARPi)

Accelerating clinical trial start-up and execution with an end-to-end approach.

IUO Validation & CDx Development

Delve into real-world data to understand biomarker prevalence and utilize comprehensive genomic profiling to support IDE studies. Establish robust analytical and clinical validation studies, aligning CDx development strategies with therapeutic trial timelines. All on a broadly distributed platform.

Learn more

Enhance clinical development with Tempus’ CDx platform

A2 Biotherapeutics uses HLA-LOH as a biomarker to progress breakthrough cell therapy.

Commercialization

Understand and take action on real-world experience

Learn more

Disease Biology

Characterizing Unmet Needs

Clinical Trial Design

Real-world Outcomes & Value

Synthesize a comprehensive view of each patient and population. Evaluate therapeutic safety, efficacy, and long-term benefits with integrated clinical, molecular, claims, and outcomes data. Generate RWE to assist regulatory decision-making, inform HEOR, and facilitate reimbursement negotiations.

Learn more

Get more insights faster with multimodal data

Tempus collaborates with Pfizer to further profile HER2 expression across various cancers.

Target Validation & Lead Optimization

Biomarker Strategy

Clinical Trial Execution

Care Gaps Closure

Leverage an AI-enabled care pathway platform that empowers providers to deliver the next step in a patient’s care journey. Integrate RWE into clinical strategies to help bridge gaps in early diagnosis, treatment adherence, and long-term patient outcomes.

Learn more

Closing biomarker testing gaps for early-stage NSCLC patients

TriHealth Cancer and Blood Institute surfaces and closes care gaps with Next.

Novel Target Identification

Indication Selection

IUO Validation & CDx Development

The operating system for precision medicine 2.0

Click the boxes below to learn more about how Tempus is advancing precision medicine throughout the drug lifecycle

Explore our customer success stories to see why Tempus is a trusted partner for 95% of the top 20 pharma companies* and more than 200 biopharma companies.

AstraZeneca

Mirati Therapeutics

Recursion

Pfizer

Sermonix

Bristol Myers Squibb

BioNTech

GSK

Eisai

Stemline Therapeutics, Inc.

MD Anderson Cancer Center

JW Pharmaceutical

Takeda

Remix Therapeutics

United Therapeutics

IFLI

TScan

Aadi Bioscience

AstraZeneca

Gilead

AstraZeneca

Kronos Bio

AstraZeneca

Actuate Therapeutics

Gilead

Sermonix

A2 Bio

AstraZeneca and Pfizer

TScan

GSK

Janssen

GSK

Kartos Therapeutics

Eli Lilly

Geisinger

Genmab

Janssen

AstraZeneca

Kronos Bio

Bristol Myers Squibb

Genmab

Kronos

William Go, SVP, Head of Development at A2 Biotherapeutics (TMod™ is a trademark of A2 Biotherapeutics)

Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

Bhavesh Ashar, Senior Vice President, Head of U.S. Oncology at Bayer

LEORA HORN, MD, Global Clinical Head for Lung Cancer & Lung Cancer Strategy. AstraZeneca

Explore by Solution

Sequencing

Data Collaborations

Biological Modeling

Companion Diagnostics

Omics Solutions

Clinical Research Organization Services

Clinical Trial Enrollment

Tempus Studies

Care Gap Solutions

AI-enabled Algorithms

Featured Resources

Enhancing psychiatric care with pharmacogenomics (PGx)

Q&A: Advancing immunotherapy biomarker identification with Immune Profile Score (IPS)

Integrating Omics in R&D: A new era of biomedical research

Tempus receives U.S. FDA 510(k) clearance for TEmpus ECG-AF, an AI-based algorithm that identifies patients at increased risk of AFib

Embracing AI in oncology: A fireside chat with industry leaders at AACR 2024

ADCs in focus: The next generation of precision medicine in oncology

Advancing transcriptional cancer therapies with Tempus’ comprehensive life science solutions

Q&A: Using AI to identify and close gaps in care for cancer patients

Accelerating ADC development with Tempus AI

Trusted by hundreds of biopharma to power drug development

Discover AI-enabled precision medicine